![psycho silo psycho silo](https://i.ytimg.com/vi/AOV4s9x3f0A/maxresdefault.jpg)
All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. This press release contains statements that constitute "forward-looking information" (" forward-looking information") within the meaning of applicable Canadian securities legislation. The Company utilizes a bio-medicinal chemistry approach to therapeutic development, in which psychoactive compounds can be utilized as a template upon which to develop precursors and analogs, both naturally and non-naturally occurring.Ĭautionary Note Regarding Forward-Looking Statements Research and development is currently ongoing for naturally occurring psychoactive tryptamines originally discovered in different varieties of hallucinogenic mushrooms, other tryptamines and phenethylamines and combinations thereof.
![psycho silo psycho silo](https://i.pinimg.com/originals/7e/57/de/7e57de0cff7097611c5b81433b2620ad.jpg)
The team has extensive experience in drug discovery based on synthetic biology and metabolic engineering as well as clinical and regulatory expertise progressing drugs through human studies and regulatory protocols.
![psycho silo psycho silo](https://cdnfiles.hdrcreme.com/71863/large/Psycho_Silo_Saloon_1_HDRcreme.jpg)
PsyBio Therapeutics is an intellectual property driven biotechnology company developing new, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health. "With these additional patent submissions, PsyBio continues to demonstrate its leadership in the biosynthetic development field by prioritizing intellectual property protection, which is necessary for us to achieve our business objectives and important for our current and future investors." "PsyBio is dedicated to leading the development of psycho-targeted therapeutic candidates in our vision to potentially improve mental and neurological health," stated Evan Levine, PsyBio's Chief Executive Officer. These filings demonstrate the Company's commitment to value creation, while also promoting scientific and methodologic advancements in the field. The patent applications submitted comprise advancements concerning production methodology, host strains and processes of production that support and allow PsyBio's novel production methodology to be globally protected. Global patent submissions further expand PsyBio's IP portfolio and support our ongoing plans for growth." "Our IP strategy fosters the developmental processes and will allow us to develop these molecules as smoothly and rapidly as possible. "Biosynthetic tryptamine production allows the development of psycho-targeted molecules as novel therapeutic candidates, with the goal to potentially help improve human health," stated Michael Spigarelli, MD, PhD, MBA, PsyBio's Chief Medical Officer. This brings PsyBio's total number of patent application submissions to twenty, making it one of the most robust portfolios in the sector. (TSXV: PSYB) (OTCQB: PSYBF) (" PsyBio" or the " Company"), an intellectual property driven biotechnology company focused upon discovery and development of novel, bespoke, psycho-targeted therapeutics to potentially improve mental and neurological health, today is announcing the filing of additional international patent applications in Europe, Africa, and Asia. 8, 2022 /CNW/ - PsyBio Therapeutics Corp.
![psycho silo psycho silo](https://live.staticflickr.com/65535/50035555461_8a980ee7e3_b.jpg)
PsyBio now has twenty patent applications in total PsyBio is continuing to increase its psycho-targeted patent portfolio, executing on its strategic priorities of innovation, development, and technology optimization